Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 20, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,000 | -- | 18,000 | |
| Jun 26, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 45,000 | -- | 45,000 | |
| Apr 10, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 50,000 | -- | 51,708 | |
| Jan 03, 2014 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 55,000 | -- | 55,000 | |
| Jun 18, 2013 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
| Jan 28, 2013 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
| Jun 04, 2012 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
| Feb 15, 2012 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
| Jun 16, 2011 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 35,000 | -- | 35,000 | |
| May 24, 2011 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,250 | $0.64 | 3,958 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.